A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Clinical trial NCT06755515 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06755515
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-26
- Primary completion
- 2028-09-01
- Enrollment
- 510
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.